RecruitingPhase 2

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

China25 participantsStarted 2026-02-01

Plain-language summary

Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Able to communicate effectively with the investigator and comply with study requirements for visits, treatment, laboratory tests, and other relevant regulations.

Exclusion criteria

✕. Poorly controlled diabetes (fasting blood glucose ≥10 mmol/L on two consecutive occasions);
✕. Poorly controlled hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg);
✕. Presence of symptomatic pleural effusion, pericardial effusion, or ascites requiring repeated drainage (\>1 time/week).

What they're measuring

PFS

Timeframe: up to 24 months

Trial details

NCT IDNCT07548060

SponsorTianjin Medical University Cancer Institute and Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-01-22

Contact for this trial

haiyan Sun

+8613920916450 hanyai@163.com

View on ClinicalTrials.gov More NSCLC Stage IV trials